New cholesterol drug AD-117: does food change how it works?
NCT ID NCT07495514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called AD-117, which is being developed for mixed dyslipidemia (abnormal cholesterol levels). The study will give a single dose to 60 healthy adults, either with or without food, to see how food changes the drug's levels in the blood and its safety. The results will help decide how to take the drug in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-117
What this could lead to
If successful, this study will show whether AD-117 should be taken with or without food, helping to design future trials for treating mixed dyslipidemia.
What could go wrong
This is a very early phase 1 study in healthy volunteers, not patients. It only measures drug levels and safety, not whether the drug actually works for the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H PLUS YANGJI HOSPITAL, Seoul,
Seoul, South Korea